Miwa Haranaka

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)

Heather Platt, José F. Cardona, Miwa Haranaka et al. · Vaccine · 2021 · 88 citations · Full text

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

Miwa Haranaka, James Baber, Yoichiro Ogama et al. · Nature Communications · 2021 · 30 citations · Full text

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19

Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida et al. · Clinical and Translational Science · 2021 · 28 citations · Full text

Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept

Keisuke Maeshima, Koji Ishii, Mikako Iwakura et al. · Modern Rheumatology · 2011 · 26 citations

Macrophage Biology, Inflammation, Allergy +12

Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept

Keisuke Maeshima, Koji Ishii, Mikako Iwakura et al. · Modern Rheumatology · 2012 · 25 citations

Inflammation, Macrophage Biology, Autoimmune Disease +9